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Background: In patients with advanced, incurable cancer, anticancer treatment may be used to alleviate
cancer-related symptoms, but monitoring of them in daily practice is rarely done. We aim to test the effectiveness
of a real-time symptom and syndrome assessment using the E-MOSAIC software installed in handheld computer
generating a longitudinal monitoring sheet (LoMoS) provided to the oncologists in a phase III setting.
Methods: In this prospective multicentre cluster randomized phase-III trial patients with any incurable solid tumor
and having defined cancer related symptoms, who receive new outpatient chemotherapy in palliative intention
(expected tumor-size response rate ≤20%) are eligible. Immediately before the weekly visit to oncologists, all
patients complete with nurse assistance the E-MOSAIC Assessment: Edmonton Symptom Assessment Scale, ≤3
additional symptoms, estimated nutritional intake, body weight, Karnofsky and medications for pain and cachexia.
Experienced oncologists will be randomized to receive the LoMoS or not. To minimize contamination, LoMoS are
removed from the medical charts after visits. Primary endpoint is the difference in global quality of life (items 29 &
30 of EORTC-QlQ-C30) between baseline and last study visit at week 6, with a 10 point between-arm difference
considered to be clinically relevant. 20 clusters (=oncologists) per treatment arm with 4–8 patients each are aimed
for to achieve a significance level of 5% and a power of 80% in a mixed model approach. Selected co- variables are
included in the model for adjustment. Secondary endpoints include patient-perceived patient-physician
communication symptom burden over time, and oncologists’ symptom management performance (predefined
thresholds of symptoms compared to oncologists’ pharmacological, diagnostic or counselling actions [structured
chart review]).
Discussion: This trial will contribute to the research question, whether structured, longitudinal monitoring of
patients’ multidimensional symptoms, indicators for symptom management, and clinical benefit outcomes can
influence patients’ quality of life and symptom distress, in a setting of routine oncology practice.
Trial registration: Current Controlled Trials NCT00477919Background
In patients with advanced, incurable cancer, anticancer
treatment may alleviate patients’ cancer-related symp-
toms and cancer-associated complications [1]. These
beneficial effects may occur even in the absence of a
tumor response [2]. In contrast, reduction of tumor size* Correspondence: florian.strasser@kssg.ch
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reproduction in any medium, provided the ordoes not necessarily imply a benefit to patients [3].
Chemotherapy may cause physical and psychosocial side
effects [4]. An important focus of treatment is therefore
to have a beneficial impact on health-related quality of
life (HRQL) [5]. HRQL was reported by health care
professionals [6] and medical oncologists [7] to be the
most important outcome in assessing the effect of pal-
liative chemotherapy. However, HRQL considerations
rated by physicians after consultation were poorly asso-
ciated with decisions regarding modification of palliative
chemotherapy [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are defined by gold standards (i.e., RECIST, CTCAE
v3.0), symptoms and syndromes, also conceptualized as
patient-reported outcomes (PROs), are yet only partially
incorporated in routine oncology care [9,10]. Symptoms,
which are subjective perceptions of patients, cannot be
measured by currently used toxicity scales [11]. Syn-
dromes are mainly clinically described patterns, a com-
bination of symptoms and clinical signs. Cachexia for
instance is the combination of the sign weight loss and
the symptom anorexia [12].
It is often assumed that an oncologist can estimate the
symptoms of the patient accurately using a regular his-
tory. However, oncologists’ perceptions may differ from
patients’ reported physical and psychosocial experiences.
In patients with advanced cancer, the assessment of rele-
vant psychological domains, but also of pain, asthenia/
fatigue, or nutritional problems are often underestimated
[13,14]. They may not be detected (lack of screening),
not be quantified by the patient or by a professional
(lack of measuring individuals’ symptom distress) [15,16]
or their impact on patients’ everyday functioning is not
taken into account (lack of estimation of the magnitude
of the problem). Physicians’ concerns about time con-
straints arising from dealing with unexpected or com-
plex symptoms may contribute to underestimation of
symptoms, [17]. In Switzerland, an average of 15 minutes
of consultation time is general practice [18].
For the monitoring of anticancer treatment, the pallia-
tive effect of chemotherapy on disease-related symptoms
and syndromes [15] has been operationalized by defining
a clinical benefit criterion. In pancreatic cancer, the end-
point of clinical benefit response (a composite assess-
ment of pain, performance status and weight) was
created to provide a way in which the impact of therapy
on tumor-related symptoms could be assessed [19] and
has become a well-accepted outcome parameter. How-
ever, outside of clinical studies its application in routine
care is limited. It can therefore be hypothesized, that
monitoring of both symptoms, clinical benefit para-
meters (as objective indicators of effect of management)
and selected interventions may result in a quality of life
benefit for patients.
There are several approaches pursued to bring
patients’ experiences and wishes to the oncology rou-
tine care including collection of patients’ symptoms
[20], palliative care needs [21], review of systems [22],
or general concerns and questions [23], immediately be-
fore the visits with physicians and/or nurses. These
studies document the proof of concept, that such moni-
toring can be applied in clinical practice. Looking at the
three elements, i.e. symptoms, clinical benefit and treat-
ments, reveals selected documented effects. Monitoring
of patients’ symptoms alone increases professionals’awareness, patient and caregiver’s satisfaction about
communication, but rarely effectiveness of symptom
management [24]. Monitoring of indicators of patients’
needs, such as declining physical function, distress,
repeated hospitalizations, or pre-defined thresholds of
symptoms alone will trigger “only” further assessment
[14]. Monitoring of current treatments (e.g. pain medi-
cations) is only effective, or general concerns and ques-
tions [23], immediately before the visits with physicians
and/or nurses. These studies document the proof of
concept that such monitoring can be applied in clinical
practice. Monitoring of patients’ symptoms alone
increases professionals’ awareness, patient and care-
giver’s satisfaction about communication, but rarely ef-
fectiveness of symptom management [24].
The feasibility of self-assessments in patients with
advanced, incurable cancer has been demonstrated for
various symptom assessment instruments, including the
Edmonton Symptom Assessment Scale (ESAS) validated
also in cancer outpatient clinics [25].
This study evaluates the effects of the E-MOSAIC
intervention, a handheld computer-based assessment of
patients’ symptoms, clinical benefit parameters and
symptom management information, delivered real-time
by the longitudinal monitoring sheet (LoMoS) to oncol-
ogists treating patients with anticancer treatment for
advanced cancer in palliative intention.Methods
This study investigates the effect of E-MOSAIC deliv-
ered to oncologists on patient outcomes during a 6 week
treatment duration applying a cluster-randomized con-
trolled design.Development of intervention tool
Patients with incurable cancer have a high prevalence of
symptoms, making it difficult to identify those symp-
toms essential for routine assessment. Therefore, we
decided to select and group the most important symp-
toms and syndromes into clusters, aiming to maintain
an adequate coverage of all important items. This ap-
proach should guide the treating physician in a replic-
able and structured way to monitor relevant (physical
and psychological) symptoms and syndromes.
The E-MOSAIC intervention was developed based on
pilot work monitoring both symptoms and clinical bene-
fit parameter in oncology care, using paper and pencil to
color bars from zero to ten. For symptom assessment,
the Edmonton Symptom Assessment Scale (ESAS) is
used [26]. The ESAS is a validated nine-item patient-
rated symptom visual analogue scale developed for use
in assessing the symptoms of patients receiving palliative
care. The single item depression of the ESAS can reliably
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strument [27].
From published lists of frequent symptoms the study
team selected 21, a number considered both feasible to
be utilized in practice and comprehensive enough [28].
As next step the E-MOSAIC software was developed,
piloted and refined with professionals and patients
resulting in the palm-based assessment E-MOSAIC
(Figure 1).
The palm-based assessment consists of three elements
(see screenshots in the Appendix), which are filled out
by the patient (element P) and the study personnel (ele-
ments G [weight] and M [medication]).
Element P Visual-Analogue Scales (VAS) of
1. Nine frequent symptoms from ESAS (pain, fatigue,
drowsiness, nausea, anxiety, depression, shortness of
breath, loss of appetite, overall well-being);Examples of instructions (Element P) 
Examples of symptom assessment (Element P) 
Examples of Element M and G 
Some screenshots of palm as illustration 
Figure 1 Screenshot from Palm as illustration.For E-MOSAIC the single symptoms of the original
ESAS were translated in German, French and Italian
language in an informal back- and forward process,
and validated preliminarily. ESAS is measured by
palm in all patients.
2. Up to three optional symptoms;
3. Patients’ estimated nutritional intake.
Element G:
1. Body weight;
2. Karnofsky Performance Status;
3. Weight loss and body height (Body Mass Index
calculated automatically).
Element M: pre-defined, simplified list for actual medi-
cation for:
1. Pain syndromes, including assessment of MEDD
(Morphin Equivalent [oral] Daily Dose);
2. Fatigue syndromes (Methylphenidate, Erythropoietin,
transfusions);
3. Anorexia/cachexia syndromes, and for edema (to
control for weight changes).
After completion of the assessments the palm is put
back to the docking station and the data are transferred
within a few seconds from the docking station to the
local computer.
The source-code of the E-MOSAIC software is copy-
protected. The software is study-specific, but may be
used for other purposes.
Longitudinal Monitoring Sheet LoMoS which is
printed immediately and put in the patient file for the
physicians’ visit by the nurse (Figure 2).
Structure of LoMoS:
1. VAS pain, pain medication (opioids calculated as
morphine-equivalent daily dose; other analgesics);
2. VAS fatigue, KPS, medication for fatigue
(Methylphenidate, Erythropoietin);
3. VAS anorexia, VAS perceived nutritional intake,
weight change, medication for anorexia (nutritional
counselling, progestins, prokinetics);
4. 6 ESAS symptoms
5. Maximal 3 of 21 symptoms selected by patient at
baseline.
After refining the software, a formal feasibility study
was performed as briefly summarized below.
Four centers participated in all or parts of the E-
MOSAIC-Feasibility-Study.
Patients filled in the E-MOSAIC in a paper-pen and a
palm version in random order.
Figure 2 Longitudinal monitoring Sheet: LoMoS.
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patients with the palm were assessed by a structured 2-
page evaluation.
62 patients (median age 64y [30–85], 25 female) parti-
cipated. 4 patients had visual impairment, 6 comprehen-
sion problems, and 1 pat was too tired. 3/62 patients did
not complete E-MOSAIC.
Median time to complete was 3 minutes. 10 patients
preferred paper and 28 palm, 16 had no preference; 50
patients agreed to continue using palm.
Palm-based symptoms (VAS) were compared with a
paper-based categorical symptom assessment (ESAS). Wil-
coxon signed-rank tests showed no significant differencesbetween palm and paper of 9 symptoms of element P
(p-value: well-being 0.089, dyspnea 0.060, the remaining
7 symptoms 0.249-0.940), but for nutritional intake dif-
ferent (a significant difference was found (.p = 0.013).
Test-retest (1 hour, n = 20) reliability of 9 symptoms
and nutritional intake was satisfactory (Cronbach alpha
0.62 - 0.94).
The E-MOSAIC intervention for this 6-week trial
Although the E-MOSAIC incorporates a module offering
the possibility for real-time measurement of clinical
benefit response and showing it in the LoMoS the dur-
ation of this study of 6 weeks treatment, classical clinical
benefit response will not be measured as an outcome,
since it needs longer observation to fulfill the criteria.
Patient population and setting
Patients are eligible who receive anticancer treatment in
palliative intention given weekly or biweekly or continu-
ous in the outpatient setting, and routine care which
typically includes weekly visits. The setting and routine
processes of care include a personal professional nursing
contact and a brief patient assessment before the
patients visit at the oncologists.
 The palliative intention of the anticancer treatment
is defined as an expected tumor response rate ≤ 20%
according to literature. To operationalize this
definition, a list of tumor types and treatment line
was composed (e.g. second line non-small cell lung
cancer).
 Patients have to be symptomatic (symptoms
measured by VAS: 0 = best, 10 =worst; average over
last 24 hours) by the cancer disease, defined as at
least one ESAS symptom>= 3/10.
 Patients have to be able to understand the language
of the E-MOSAIC assessment and the study related
information, written informed consent and the
physician is able to communicate with the patient
studied without major difficulties (i.e., culture,
language, speech).
Eligible oncologists
Participating oncologists need to be
 experienced in medical oncology and working in a
study center or practice, who are likely not to
change standard of care for symptom assessment or
for major communication skills and who are likely
to stay in the participating institution for the time
required to treat at least 5 study patients;
 authorized to communicate with the patient about
all aspects of cancer care and be authorized to
independently perform immediate changes of
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institutional requirement to counsel another
colleague before prescriptions;
 familiar with communication skills, defined as
completion of a basic communication skills course
or an equivalent training.
Trial design
A cluster-randomized 2-arm design is used to test the
E-MOSAIC intervention with the LoMoS given to phy-
sicians. At enrolment each participating physician will
be randomly allocated to one of the 2 arms (standard
care, E-MOSAIC+LoMoS) at 1:1 ratio stratified accord-
ing to the institution. All eligible patients to be treated
by the physician will be under the same intervention
(Figure 3).
After the registration, the palm will recognize the on-
cologist (scroll bar) and automatically provide the soft-
ware for the control or the E-MOSAIC arm, respectively.
After synchronization the unique patient number (UPN)
will be updated immediately, with maximal 12 patients
per oncologist only 12 patient-UPNs will be possible.
This trial design was chosen in order to minimise
contamination. Several patients allocated to the same
physicians can hardly be considered independent. In
particular, a physician familiar to the LoMoS interven-
tion would probably treat his patients in a similar way,
even if they were randomized to different interventions.
To prevent this contamination, physicians are chosen as
clusters [29]. Cluster randomisation is a standard ap-
proach to evaluate both process outcomes and patient
outcomes, and is considered especially relevant if the
intervention is on physician level and outcomes are pa-
tient reported [30].
Randomization procedure and patient registration
Participating physicians are randomly allocated to the
intervention or control arm. Hence, all eligible patients
allocated to a physician will be under the same
intervention.
Before randomization, the center needs to be activated






Figure 3 Randomization with intervention.has to be informed about the study procedures and has
to sign informed consent prior to his randomization.
There will be no specific training on symptom manage-
ment, because the E-MOSAIC intervention in this study
includes simply the monitoring sheet. Patient registra-
tion is only possible for randomized physicians. Patients
give informed consent prior to any protocol-specific
procedure.
Data collection procedures
Patients are seen in all clinics first by oncology nurses
who perform the baseline visit, educate patients about
the use of the palm, ask patients about oncologist’ inter-
ventions in the previous week, and perform at weeks 3
and 6 the outcome assessments.
At baseline, weeks 3 and 6, the cognitive status of
patients is assessed.
Since mild cognitive impairment is well reported to be
underestimated but influencing patients’ ability to ex-
press subjective experience of well-being and symptoms,
cognitive function will be monitored throughout the
study (Figure 4).
To screen for patients with cognitive impairment at
baseline, the Mini-Cog, a brief cognitive screening test,
will be used. The Mini-Cog and the Mini-Mental Status
Examination applied post-hoc to an existing population
revealed similar sensitivity (76% vs. 79%) and specificity
(89% vs. 88%) for dementia. Therefore, the Mini-Cog
test is feasible in settings where time is short, training
of personnel is not possible and/or language barriers
exist [31].
Objectives and endpoints
The objective of the study was to evaluate the effects of
the intervention using E-MOSAIC palm and real-time
longitudinal monitoring sheet (LoMoS) in patients re-
ceiving anticancer treatment for advanced cancer in pal-
liative intention.
Change in Global Quality of Life (G-QoL) is the pri-
mary endpoint. The difference in G-QoL between
baseline and after last study visit is measured. The
change in QoL will be assessed using the EORTC-Patient / nurse:  
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Figure 4 Study flow with visits and forms.
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single item measures. Patient will complete the EORTC-
QlQ-C30 at baseline and at week 3 and 6 after con-
sultation. G-QoL is the composite score of questions
29 and 30. This instrument is well validated, frequently
used and provides a large data base of normative data
[32].
Secondary endpoints are the number of patients having
a G-QoL response, physician-patient communication,
symptoms and syndromes and symptom management
performance.
Responders are defined as having a better rated G-QoL
assessment after last study visit compared to baseline of
more than half of standard deviation of the G-QoL
changes of whole study population.
Patients’ estimation of the patient-physician communi-
cation will be assessed by a physician compassion rating
and general physician attribute rating scales (27).
– The rating of the physician compassion uses a
semantic differential format including five pairs of
physician characteristics. The characteristics are
warm-cold, pleasant-unpleasant, compassionate-
distant, sensitive-insensitive, caring-uncaring. Thetwo attributes are the left and right anchor of a
100 mm line with each item ranging from 0–100.
This scale has been reported to be internally
consistent (Cronbach’s alpha coefficient, .92) in
cancer survivors and non-cancer patients. A
composite score can be calculated (ranging from
0 to 500) [33].
– For general physician attributes five other pairs
of statements in a semantic differential format
will be used: 1) wants best for patients, 2) patient
involvement in decision-making, 3) encourage
patients’ questions, 4) acknowledging patients’
emotions, and 5) caring for patients. Patients
will be asked to rate each of the questions in a scale
of 0 (worst) to 100 (best).
Physician’s estimation of the patient-physician commu-
nication will be assessed by a questionnaire comprising
7 ad-hoc statements covering satisfaction with amount
and clarity of provided information, estimation of
patients’ comprehension of information and satisfaction
of patient involvement in decision making process. This
evaluation tool was developed for the SAKK communi-
cation trial [34].
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ware between baseline and after last study visit will be
evaluated. Symptom Distress Score, the summation of
the nine ESAS items is used as in the original publica-
tion [35]. All ESAS symptoms are individually investi-
gated, to test the hypothesis, that the E-MOSAIC
intervention may influence only specific symptoms (e.g.,
only anxiety and depression, but not pain, or vice versa).
As syndromes, pre-defined selected items, the KPS,
weight and weight loss, nutritional intake, and use of
medical interventions for symptoms (e.g. MEDD) are
compared. Several of these items have been conceptua-
lized as clinical benefit criteria.
Number of visits with a symptom load above defined
threshold for 5 symptoms without immediate interven-
tion and all interventions performed by the oncologist to
alleviate multidimensional suffering of patients and fam-
ily members will be calculated and oncologists’ routine
work will be collected. From the visits all routinely avail-
able information describing physician’ diagnostic or
therapeutic interventions are collected: visit flow sheets,
visit notes and reports, lab sheets, order sheets, and
nurses’ notes.
To capture interventions made by the oncologist for
any of the multidimensional (symptom) problems, which
the patient recalls one week later, the patient will be
asked before each visit: “did your doctor prescribe or
initiated treatments or interventions to relieve your
physical, emotional, or social distress/burden, and if so,
please briefly mention them.”
To compare the number of interventions made for key
symptoms above defined thresholds. For this study is
chosen:
 visits (#) with pain > = 6/10 and no immediate
change of analgesics
 visits (#) with fatigue > = 9/10 and no immediate
diagnostic or therapeutic intervention
 visits (#) with anorexia > = 9/10 and no immediate
diagnostic or therapeutic intervention
 visits (#) with depression > = 6/10 and no immediate
diagnostic or therapeutic intervention
 visits (#) with shortness of breath > = 6/10 and
no immediate diagnostic or therapeutic
intervention
A medical fellow, having at least 2 years clinical ex-
perience, who is blinded to the randomisation (the UPI
system does not allow to identify institutions nor indi-
vidual oncologists), will analyse for each patient the visit
description and patient recalled interventions of last visit
to search for such interventions.
From the visits the following variables are collected:
medications and changes, diagnostic interventions,delegated interdisciplinary interventions, and patient
perceived interventions.
Additional research questions investigate factors influ-
encing change in G-QoL, tumor response (CR, PR, SD
or PD), tumor type, predominant symptom, anxiety,
complexity, education and hospitalization. A predomin-
ant symptom is defined as the symptom with the highest
ranking and all other symptoms are > =2 / 10 lower
ranked. Complexity is defined as > =3 symptoms with >
=6/10, with the exception of fatigue and anorexia
(threshold > =9/10).
To explore patients’ subjective adaptation to illness
and burden of treatment two linear analogue self-
assessment (LASA) indicators are included, assessing
perceived adjustment to chronic illness (PACIS); [34]
(‘no effort at all’ – ‘a great deal of effort) and overall
treatment burden (‘not at all’ – ’severely’). The indicator
for PACIS was confirmed to be responsive to cytotoxic
side-effects, mental distress, and psychosocial dysfunc-
tion in patients with early breast cancer [36]. It is suit-
able to describe patients’ adaptation over time. The
instruments are validated [37]. The indicator for overall
treatment burden has been validated regarding side-
effects of antiemetic and cytotoxic therapy [38].
As indicator for decision-making preferences, the dif-
ference in number of mismatched decision-making pre-
ferences between week 3 and 6 will be compared
between the two arms.
Patients’ preferences for involvement in decision mak-
ing will be assessed by a measure adapted from previous
studies [39]. The patient chooses from among five cat-
egories ranging from ‘the doctor should make the deci-
sion using all that he/she knows about the treatment’ to
‘I should make the decision using all that I know and
learn about the treatment’. In addition the physician is
asked to choose from among the same five categories
how he/she estimates the patients’ preferences.
A mismatch is defined as follows: the patient ranks #1
or #2 and the physician #4 or #5 or vice versa. For neu-
tral patients or physicians no mismatch is possible per
definition.
Sample size calculation
Sample sizes are calculated for an inequality test for two
means of change in QoL in a cluster randomized design
using the software package NCSS 2004 - PASS 2002,
according to the formulation of Donner and Klar, as-
suming a two-sided significance level of 0.05, and a stat-
istical power of 0.8 [40]. Further assumptions on design
parameters are an overall variance (s2) of 400, an
intracluster correlation coefficient (ICC, estimated by
the ratio of between-cluster variation to overall variance)
of 0.05 , an effect size (between-arm difference in G-
QoL to be detected) of 10, and the cluster size (the
Blum et al. BMC Palliative Care 2012, 11:19 Page 8 of 12
http://www.biomedcentral.com/1472-684X/11/19number of evaluable patients per physician) [40]. For the
cluster size several options are considered, but it is
expected to stop the trial at a cluster size of 8 with 12
physicians per arm, yielding a total sample size of 192
evaluable patients.
Since the initial estimate of the ICC might not be ap-
propriate, an interim analysis to adjust the sample size
as suggested in Lake et al. is foreseen [41]. Once data for
the first 100 patients are available, estimates of within-
cluster variation and between-cluster variation are
obtained. If the resulting ICC has to be at least 1.5 times
larger than the value taken for the initial sample size es-
timation, then the sample size would be adjusted using
the new estimate of ICC, without alteration on other de-
sign parameters. The feasibility of patient accrual is eval-
uated at the same time. The recommended cluster size
might be adjusted accordingly.
Data analysis
Due to the cluster structure, comparisons of different
outcomes between treatment arms will be analyzed by
mixed models. For endpoints with continuous values,
linear mixed model may be applied. For endpoints with
categorical or binary values, nonlinear mixed model or
generalized estimating equations may be applied.
The data will be stored and analyzed at the SAKK
Coordinating Center using SAS software, Version 9.2 of
the SAS System for Windows (SAS Institute Inc., Cary,
NC, USA) and the open source R statistical software
package (http://www.r-project.org/). All statistical tests
will be done two-sided at a significance level of 0.05.
P-values will be corrected for multiple testing where
appropriate.
Descriptive statistics will be done by median and range
for continuous variables. Categorical data will be
reported using absolute and relative frequencies.
For the primary endpoint, selected influential variables
(education, tumor type, predominant symptom, anxiety,
complexity, hospitalisations) and the baseline G-QoL
value will be included in the analysis model as covari-
ates. For the primary analysis, only evaluable patients
will be used. As a sensitivity analysis, non-evaluable
patients will be included if possible. For instance, the dif-
ference between baseline and 3 weeks will be analyzed
including patients who are evaluable at week 3 but non-
evaluable at week 6.
Several pre-defined subgroup analyses are foreseen:
The difference in G-QoL will be compared between both
arms in sub-groups of patients having
a) a tumor size response (SD, PR, CR) or not (PD),
b)basic education or additional education
c) one of the main tumor types defined as
composing > = 20% of the evaluable study patients.d)a predominant symptom, if composing > = 20% of the
evaluable study patients (expected based on symptom
epidemiology data: pain, anorexia and/or fatigue
[both predominant vs. other symptoms or alone vs.
other symptoms], anxiety and/or depression [both
predominant vs. other symptoms or alone vs. other
symptoms], nausea, shortness of breath).
e) anxiety <6/10 or > =6/10
f ) complexity less than 3 symptoms above threshold vs.
> = 3 symptoms above threshold (fatigue and
anorexia > =9/10, other symptoms > =6/10).
All subgroup analyses will include baseline G-QoL as
covariate.
The study population will be described separately by
institution (study center)-, oncologist-, and patient-
related factors.
The study center will be described with regards to ac-
tual procedures of symptom and syndrome assessment
at the participating institution and local available inter-
ventions for multidimensional symptom and syndrome
management.
From the participating oncologists following data are col-
lected: Gender, age, mother language, living >=6 months in
the language region and Board certification oncology.
The patients included will be characterized with re-
spect to socio-demographic variables, cognition, and dis-
ease and treatment-related variables.
Ethical considerations
This protocol was written, and the study is to be per-
formed in accordance with the Declaration of Helsinki
and the Guidelines of Good Clinical Practice issued by
ICH. The study has been approved by the local ethics
committees of the cantons of all participating centers
(Aarau, Basel, Bern, Zuerich, Fribourg, Graubuenden,
St.Gallen, Ticino). There is no approval outstanding.
All patients are informed of the aims and procedures
of the study. They are informed as to the strict confiden-
tiality of their data, but they need to know that their
medical records may be reviewed for study purposes by
authorized individuals other than their treating
physician.
Informed consent is obtained on a written form
approved by the local ethics committee. Two copies of
the informed consent have to be signed, one of which is
handed to the patient.
Patients have the right to refuse further investigations
for any reason and at any time. Patients who decide to
withdraw from the study should be asked whether they
also want to withdraw their consent for their data to be
used for the follow-up assessments. It is emphasized that
participation is voluntary and that the physician is
allowed to refuse further participation in the study
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obtained on a written form.
Discussion
This study evaluates the effects of longitudinal assess-
ment of symptoms and syndromes in patients receiving
anticancer treatment for advanced cancer in palliative
intention on health related quality of life, symptoms,
communication and physicians performance.
Interim analysis
The interim analysis was based on the data from 89
patients coming from 31 different physicians. Of those,
the data from 8 patients could not be used, since they
were assigned to physicians who enrolled only one pa-
tient, i.e. they cannot be used to estimate within cluster
correlation. At that time already 160 patients allocated
to 47 physicians had been accrued. Unexpectedly a nega-
tive ICC was found. A literature search on negative ICCs
only revealed that this appears in case of very similar
but rather small clusters [42]. This translates to a negli-
gible between-cluster variation and a dominant within-
cluster variation which in turn is the case for very small
ICCs. Then a simulation study using the design para-
meters of this trial and a SAS macro for power calcula-
tions (fpower.sas) was performed [43]. It seemed that an
increasingly negative ICC does not diminish the power,
but rather that the power increases further. Hence the
sample size was not adapted for this reason.
However, during the interim analysis three problems
arose regarding the sample size:
a) None of the predefined scenarios met the reality of
cluster sizes accumulated in the first three years:
instead, the vast majority of clusters were smaller
than expected.
b)An unexpectedly high number of patients were not
evaluable for primary endpoint according to the
requirements specified in and implied by the
protocol. Although the original protocol focused on
evaluable patients, it did not foresee additional
patients to be accrued to account for non-evaluable
patients.
c) There were many clusters with only one or two or
even no patients. These are problematic because they
do not allow to properly calculating the within-
cluster correlation required for the interim and final
analysis. In fact, this renders patients who are
evaluable of limited value for the analysis. While the
trial design allows for varying and even small cluster
sizes it is not clear how these very small clusters will
affect the final results. Moreover, while there are
approximate formulae to adjust the final sample size
for varying cluster sizes, these only apply toapproximate calculations which were not used
during the trial development. These problems
revealed from the interim analysis led to the
following conclusions which were documented in a
note to file:
1) 160 patients will be required, distributed to four
patients per cluster with twenty clusters per
treatment arm.
2) An additional five per cent, i.e. eight patients, will
be accrued to account for varying cluster sizes.
3) That is, in total 168 evaluable patients will be
accrued to meet the design specifications of the
protocol (alpha = 5%, power = 80%).
Because of the problems described in b) and c) even
240 accrued patients (the maximum foreseen in the
protocol although there only evaluable patients were
mentioned) would not have been sufficient to obtain 168
evaluable patients. Hence, it was decided by the trial
team members at the SAKK CC on April 20, 2011 to ac-
crue an additional 10 percent, i.e. 24 patients, resulting
in a total of 264 patients.
Context
Several studies assessed whether the provision of HRQL
data to oncologists, using touch pad symptom assess-
ment devices, [24,44] by using prompt sheets [45,46] or
summaries of HRQL, [47] improve communication be-
tween oncologist and patient and symptom control. The
provision of a summary of HRQL (EORTC-QLQ-C30)
to patients and oncologists in a randomized crossover
trial resulted in more frequent discussion of HRQL
issues and detection of unexpected psychosocial topics
and symptoms [14].
Longitudinal symptom assessment by means of com-
puters is feasible in the multicenter setting even for a
long time span. In a recently published study patients
were invited to report symptoms (Common Termin-
ology Criteria for Adverse Events CTCAE) on an online
platform. Of 125 invited, 105 participated for the mean
length of one year and showed a high compliance and
high satisfaction with the system, however there was
only a marginal effect on communication [11].
Randomized controlled trials focused mainly on im-
provement of communication and symptom distress. A
palm based interactive tailored patient assessment, con-
taining a selection of symptoms, problems and concerns,
rating of this items from 1–4 and prioritization for sup-
port was tested in 145 lymphoma and leukemia patients
in a single centre in Norway. The assessment output was
immediately delivered to treating physicians and nurses
in the intervention group. The outcomes measured were
the same assessments: Numbers of symptom problems
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and need for support. In the intervention group there
were more symptoms addressed, less symptom distress
measured and patient were less in need for symptom
management support [48].
A second randomized controlled trial investigated the
effect of the ESRA-C (electronic self-report assessment
cancer) on in 660 cancer patients at two institutions.
The output from the ESRA-C was displayed to the
treatment team in the intervention group. The primary
outcome was the likelihood of discussion of symptoms
and quality of life issues (SQLIs) between clinicians
and patients and the secondary endpoints the visit dur-
ation and the perceived usefulness by clinicians. When
the SQLIs were considered as problematic, they were
more frequently discussed during the visit in the inter-
vention group; the length of visit time was equal be-
tween the two groups. The clinicians perceived the
output as useful [20].
Strengths
The strength of our approach, is the defined clinical set-
ting, chemotherapy in palliative intention, where disease
related symptoms, treatment related toxicities and clin-
ical benefit parameters guide treatment.
In contrast to the previous studies which aimed at a
general improvement of communication our study aims
to improve symptom control due to more in depth
symptom assessment and adaption of chemotherapy due
to better monitoring of toxicity and clinical benefit
parameters.
A second strength is the multicenter setting which
tests the intervention in a real life environment and dif-
ferences between centers can be further studied.
The main focus on specific and generic patient
reported outcomes (quality of life, and symptoms)
reflects patient centered care in the oncological setting.
Limitations
E-MOSAIC intervention may be effective on several
levels (i.e., awareness of patient, awareness of physician,
coping, symptom control, communication), this study
tests the hypothesis to overall improve the quality of pal-
liative cancer care, rather than focusing on specific out-
comes only. Global single-item QoL indicators are
similarly efficient as multi-item scales for overall treat-
ment comparisons and changes over time because they
reflect the summation of the individual meaning and im-
portance of various factors [38]. The use of a single-item
tool to appropriately obtain a measure of overall QoL
was reported from a cooperative multicenter study set-
ting [49].
Patient-rated QoL may be influenced by many factors.
Disease and treatment-related as well as social andcultural factors are essential for any individuals’ estima-
tion or judgment of their QoL. Therefore we correct for
known influential factors in the analysis.
The differences between the randomised physicians
may have a bigger influence than the intervention, espe-
cially on communication. Patient-physician communica-
tion can affect the psychological distress and quality of
life of cancer patients [50]. Informativeness, interper-
sonal sensitivity, and partnership building, three
dimensions of communication, are related to patient
satisfaction, compliance, and medical information re-
call [51]. Several elements of the patient-physician
communication have been emphasized, such as recog-
nition of patients’ main concerns related to physical
but also emotional dimensions, fulfilling the patients’
individual and general information needs, [52-54] a
physician-communication style reflecting empathy,
care, compassion, and understanding of patient’s diffi-
culties to cope, [55] physicians’ ability to break bad
news [56,57] and recognition of patients decision-
making preferences [58].
The management of common symptoms is part of
oncologists’ professional skills. The Global Core Cur-
riculum for Medical Oncology (ASCO/ESMO) includes
supportive and palliative care items and the Quality
Cancer Care statement of ASCO and ESMO includes
pain management, supportive and palliative care [59].
A large body of evidence builds the foundation for
practice guidelines in symptom management of
advanced cancer patients, allowing agreed-on classifica-
tions of various types of symptom control interven-
tions and thresholds of symptom expression. However,
as in other medical disciplines, variability in symptom
management practice is common, driving academic
exchanges including research and scholar literature.
Therefore, in this study, no practice guidelines are pro-
vided nor explored.
The reactions to symptoms may therefore vary be-
tween physicians as well as the documentation of the
interventions.
Future
The E-MOSAIC study carries the potential to improve
certain aspects of clinical management in daily oncology
practice for patients with advanced, incurable cancer by
simple, real-time, longitudinal monitoring of patient-
reported outcomes. The intervention tested is a step to-
wards the development of longitudinal clinical benefit
outcome strategies for disease-oriented trials.
A well-accepted and feasible instrument to document
patient-reported outcomes may improve the use of anti-
neoplastic treatments in patients with advanced cancer.
As a potentially relevant spin-off of the E-MOSAIC
study, the interdisciplinary collaboration of oncology
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cies of oncology nurses in patient care may become bet-
ter acknowledged.
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